This site is intended for Healthcare professionals

Facebook
LinkedIn
Twitter

HELP US PUT A SPOTLIGHT ON HEART FAILURE

Despite significant advances in heart failure (HF) treatment and prevention, morbidity and mortality remain high.1

Every heart failure patient, regardless of symptoms, remains at risk.

 


9 out of 10 patients

Even with current HF standard of care, the majority 9 out of ten patients remain symptomatic and are still at risk of hospitalisation for heart failure and cardiovascular death2*

9 out of 10 patients

Even with current HF standard of care, the majority
9 out of ten patients remain symptomatic and are still
at risk of hospitalisation for heart failure and
cardiovascular death2*

Heart failure patients with reduced ejection fraction,
including those who may appear stable, have an unacceptably
high risk of hospitalisation and even death3

CV death or hospitalisation
based on NYHA II classification over a 4 year period

Data from the CHARM study, (2003)


Approximately 5 out of 10 patients

will die within 5 years after diagnosis4

Approximately 5 out of 10 patients

will die within 5 years after diagnosis4

In fact, HF is the leading cause of hospitalisation in patients over the age of 65.5

A BLIND SPOT

Despite the significant burden of HF, a new global survey shows that heart failure is a ‘blind spot’ for the public
and policymakers.
 

The survey, commissioned by AstraZeneca, in partnership with the World Heart Federation (WHF), showed low awareness
among policymakers of the societal and economic burden of the disease, and low awareness among the public on the
signs and symptoms of HF.6,7


190 policy makers from US, Canada, UK, Italy, Germany and Spain were surveyed in our recent study on HF awareness.
Of those,

Awareness of HF’s connections to hospital admissions is low among policymakers

Of those surveyed in our recent study on HF awareness,

Awareness of the 3 main symptoms is low amongst the general public surveyed

23%
Shortness of breath when
resting or being active

 

40%
feeling unusually
tired or weak

 

25%
Swelling of the feet, ankles, legs,
abdomen, or the small of the back

23%
Shortness of breath when
resting or being active

40%
feeling unusually
tired or weak

25%
Swelling of the feet, ankles, legs,
abdomen, or the small of the back

 

 

People were asked to select one disease for each symptom from a list of heart failure, diabetes, heart attack, stroke or asthma
 

People who connected symptoms with HF, compared to other conditions7,9

 

SPOTLIGHT ON HEART FAILURE


In order to bridge this gap, AstraZeneca and the World Heart Federation have partnered
on the Spotlight on Heart Failure campaign, designed to educate people about heart failure and
improve the prognosis for those who have been diagnosed.

Together we aim to:

1

Reduce the number of new
heart failure cases

2

Reduce the number of deaths
caused by heart failure

3

Reduce the frequency of hospitalisation for people living with heart failure

4

Improve the lives of people
suffering from heart failure and the
ones who care for them

 

1

Reduce the number
of new heart
failure cases

2

Reduce the number
of deaths caused by
heart failure

3

Reduce the frequency
of hospitalisation for
people living with
heart failure

4

Improve the lives of
people suffering from
heart failure and the ones
who care for them

But the launch of this campaign is just the beginning.
We want to create a global movement to shine a light on
heart failure and improve the lives of everyone affected by it.

We want
your
expert
opinion
to help
shape this
campaign.

So we are asking -
what issues matter most to you?

World Heart Federation and Astrazeneca logos

Working together to shine a spotlight on heart failure
and promote heart health around the world.

Working together to shine a spotlight on heart failure and promote heart health around the world.